Lannett Receives FDA Approval for Loxapine Capsules, 5 MG, 10 MG, 25 MG and 50 MG
Lannett Company, Inc. today announced it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application of Loxapine Capsules, 5 mg, 10 mg, 25 mg and 50 mg, which are therapeutically equivalent to the reference listed drug, Loxitane Capsules, 5 mg, 10 mg, 25 mg and 50 mg from Watson Pharmaceuticals.

All Approvals Are Not Created Equal
MELA's EU approval isn't nearly as important as one stateside.

FDA Approvals Expected to Put Apricus Bio on Profitable Path
August has been a huge month for San Diego-based Apricus Biosciences Inc.